Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
leuprolide acetate
|
| gptkbp:administrativeDivision |
monthly
deltoid muscle gluteal muscle every three months |
| gptkbp:availableSizes |
30 mg
45 mg 22.5 mg 7.5 mg |
| gptkbp:clinicalTrials |
palliative care
Phase III long-term treatment |
| gptkbp:commonName |
gptkb:Lupron
gptkb:Eligard Viadur |
| gptkbp:contraindication |
pregnancy
breastfeeding hypersensitivity to leuprolide |
| gptkbp:date |
1985
|
| gptkbp:dosageForm |
1-month depot
3-month depot |
| gptkbp:drugInterdiction |
anticoagulants
antineoplastic agent prescription only antidiabetic medications CYP450 substrates hormonal agent |
| gptkbp:formFactor |
depot injection
|
| gptkbp:healthcare |
bone density
hormone levels blood glucose |
| https://www.w3.org/2000/01/rdf-schema#label |
Lupron Depot
|
| gptkbp:manufacturer |
AbbVie
|
| gptkbp:marketedAs |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:offers |
varies by region
can be expensive |
| gptkbp:patentExpiration |
2025
|
| gptkbp:patentStatus |
patented
|
| gptkbp:patentType |
yes
|
| gptkbp:route |
intramuscular injection
|
| gptkbp:sideEffect |
fatigue
nausea weight gain mood changes hot flashes |
| gptkbp:storage |
room temperature
protected from light |
| gptkbp:triggerType |
GnRH agonist
|
| gptkbp:usedFor |
prostate cancer
endometriosis precocious puberty |